Insider filings

SELLAS Life Sciences Group, Inc. (SLS)

Biotechnology, listed on NASDAQ.

28 insider transactionslast filed Nov 20, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

GetSignal NewsCompany release · Nov 20, 2026

SELLAS Life Sciences Group closes public offering for $172.5 million gross

The offering included the full exercise of the underwriters' option to buy 1,730,769 additional shares at $13.00 per share.

Written by GetSignal with AI from SEC filings and the company’s own press releases; each article links to its source. Not investment advice.

Read the article

EarningsQ3 FY2026 · reported Nov 12, 2026

Q3 FY2026: In line, GAAP. Next report Mar 25, 2027.

EPS Q3 FY2026

Reported-$0.05
Consensus-$0.05

Beat 4In line 1Miss 1

EPS against the consensus, quarter by quarter. Outlined: a GAAP figure against an adjusted consensus.

Consensus -$0.05 a share on $36.1M of revenue, the analysts’ forecast.

Every quarter

Money managers13F filings for Sep 30, 2026

166

institutions reported SELLAS Life Sciences Group shares in 13F filings for Sep 30, 2026. BlackRock, Inc. held the largest stake, $199.2M.

The largest holders

BlackRock, Inc.$199.2M
State Street Corp$127.7M
Vanguard Capital Management LLC$110.1M
Every holder

Insider tradesForm 4 · 7 open-market filings shown

Four open-market purchases and 3 sales.

May 22, 2025Nov 18, 2026

PurchasesSales

4 purchases3 sales

A median 2 business days from trade to filing. Form 4 is due within two.

Every filing
Companyfrom the company's filings and listing, as of Nov 18, 2026

About SELLAS Life Sciences Group, Inc.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Chief executive
Angelos Stergiou
Employees
13
Listed since
Mar 12, 2008
Market value
$3.9B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$0.18
Dividend yield
-

www.sellaslifesciences.com

GetSignal News3 articles · newest first

GetSignal News

HeadlineSourceDate
SELLAS Life Sciences Group closes public offering for $172.5 million grossThe offering included the full exercise of the underwriters' option to buy 1,730,769 additional shares at $13.00 per share.Company releaseNov 20, 2026
SELLAS Life Sciences Group prices 11,538,462-share offering at $13.00 per shareThe company said it expects gross proceeds of $150.0 million before underwriting discounts and commissions and offering expenses.Form 8-K and releaseNov 17, 2026
SELLAS says Phase 3 REGAL trial of galinpepimut-S met its primary endpoint in AMLIn the trial, the cancer vaccine reduced the risk of death by 41% compared with best available treatment.Form 8-K and releaseNov 17, 2026

Written by GetSignal with AI from SEC filings and the company's own press releases; each article links to its source. Not investment advice.

All company news

Earnings6 reported quarters · next on Mar 25, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Nov 12, 2026-$0.05-$0.05n/an/aEPS in line, GAAPRevenue n/a
Q2 FY2026reported Aug 11, 2026-$0.05-$0.05n/an/aEPS miss, GAAPRevenue n/a
Q1 FY2026reported May 12, 2026-$0.05-$0.06n/an/aEPS beat, GAAPRevenue n/a
Q4 FY2025reported Mar 19, 2026-$0.05-$0.06n/an/aEPS beatRevenue n/a
Q3 FY2025reported Nov 12, 2025-$0.06-$0.06n/an/aEPS beat, GAAPRevenue n/a
Q2 FY2025reported Aug 12, 2025-$0.07-$0.08n/an/aEPS beat, GAAPRevenue n/a

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on SLS yet. All earnings call briefs.

13F filings13F positions as of Sep 30, 2026

Institutional holders

HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$199.2M16,181,634+7.4%8.55%
State Street Corp$127.7M10,373,074-20.2%5.48%
Vanguard Capital Management LLC$110.1M8,942,647+8.7%4.73%
Geode Capital Management, LLC$63.7M5,171,819+5.9%2.73%
Susquehanna International Group, LLP$32.5M2,638,466+28.7%1.39%
Vanguard Portfolio Management LLC$28.3M2,297,581+6.3%1.21%
Northern Trust Corp$22.8M1,851,069+14.3%0.98%
Charles Schwab Investment Management Inc$22.2M1,801,579+218.9%0.95%
Morgan Stanley$18.6M1,511,107+22.2%0.80%
UBS Group AG$18.3M1,485,280+18.6%0.79%
Vanguard Fiduciary Trust Co$17.7M1,441,271+7.9%0.76%
Dagco, Inc.$16.5M1,336,449+8.4%0.71%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Sep 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Form 47 filings shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
Angelos M. StergiouPresident and CEOSold26,606$19.18$510KNov 18, 2026filed Nov 20, 20262d
Dragan CicicSVP, Chief Development OfficerSold6,933$19.18$133KNov 18, 2026filed Nov 20, 20262d
John Thomas BurnsCFOSold3,831$19.18$73KNov 18, 2026filed Nov 20, 20262d
Katherine Bach KalinDirectorBought63,400$1.59$101KNov 19, 2025filed Nov 21, 20252d
Robert L. Van NostrandDirectorBought10,000$1.48$15KJun 12, 2025filed Jun 13, 20251d
Jane WasmanDirectorBought20,000$1.69$34KMay 30, 2025filed Jun 2, 20251d
Katherine Bach KalinDirectorBought20,000$1.80$36KMay 22, 2025filed May 22, 20250d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (15)
InsiderEventSharesDate
Angelos M. StergiouPresident and CEOStock award1,065,000Jun 16, 2026
Jane WasmanDirectorStock award50,000Jan 7, 2026
Katherine Bach KalinDirectorStock award50,000Jan 7, 2026
John Thomas BurnsCFOStock award300,000Jan 7, 2026
Dragan CicicSVP, Chief Development OfficerStock award300,000Jan 7, 2026
David A. ScheinbergDirectorStock award50,000Jan 7, 2026
Robert L. Van NostrandDirectorStock award50,000Jan 7, 2026
John VarianDirectorStock award50,000Jan 7, 2026
Angelos M. StergiouPresident and CEOOther (see filing)187,066Dec 3, 2025
John Thomas BurnsCFOOther (see filing)58,592Dec 3, 2025
Dragan CicicSVP, Chief Development OfficerOther (see filing)63,800Dec 3, 2025
Jane WasmanDirectorStock award31,000Jan 10, 2025
David A. ScheinbergDirectorStock award31,000Jan 10, 2025
Angelos M. StergiouPresident and CEOStock award886,650Jan 10, 2025
John Thomas BurnsCFOStock award363,800Jan 10, 2025

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

Data as of Nov 21, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on SLS show and how current they are.

Are insiders buying or selling SLS?

Across the 7 most recent open-market filings shown here, 4 were purchases and 3 were sales.

How quickly are SLS trades disclosed?

Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows.

Related companies

also in Healthcare

Stocks A to Z